To our knowledge, there have been a few previously reported children with anti-GAD-associated LE. In LE associated with anti-GAD, brainstem involvement is rare. Here, we present a 15-year-old boy with brainstem symptoms associated with anti-GAD antibodies.
Introduction
Limbic encephalitis (LE) is a neurological syndrome that may present in association with paraneoplastic and non-paraneoplastic causes. Non-paraneoplastic LE may be associated with systemic autoimmune disorders, autoantibodies to cell membrane antigens such as voltagegated potassium channels (VGKCs), and, less frequently, autoantibodiesto intracellular antigens such as glutamic acid decarboxylase (GAD). [1] [2] [3] GAD has been recently identified as a target of humoral autoimmunity in a small subgroup of patients with nonparaneoplastic LE. Anti-GAD antibody-associated LE is a rare inflammatory brain disease characterized by subacute memory loss, psychiatric symptoms, seizures, and sometimes signal abnormalities involving the mesial temporal lobes and other areas of the limbic system. Besides that, the neurologic spectrum of anti-GAD autoimmunity also includes brainstem, extrapyramidal, and spinal cord syndromes. [4] [5] [6] Limbic encephalitis with antibodies to glutamic acid decarboxylase presenting with brainstem symptoms abnormalities both temporal regions. Cerebrospinal fluid sample (CSF) showed normal protein and cellular content. Serological and CSF assays for infectious agents, including viral etiologies, Mycoplasma pneumoniae, Chlamydiapneumoniae, and Lyme, were negative. A serological panel for autoimmune disorders was negative, including erythrocyte sedimentationrate, C-reactive protein, anti-nuclearantibodies, double-stranded deoxyribonucleic acid (DNA) antibody, romatoid factor, and complement levels.The nerve conduction studies and spinal MRI were also normal.
All evaluation of him did not suggest the possibility of infections, neoplasms, or toxic or metabolic etiology. We suspected limbic encephalitis but searching for anti-neuronal antibodies (antiHu, Yo, Ri, LGI1, CASPR2, Ma2/Ta, CRMP5/CV2, amphiphysin, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor [AMPAR] , and N-methyl-D-aspartate receptor [NMDAR]), could not performed in our hospital. However, only anti-GAD antibodies could be performed with highly positive titers.
On the basis of the clinical and laboratory findings, the patient was diagnosed as non-paraneoplastic LE with anti-GAD antibodies. Levetiracetam therapy was started for EEG findings. Intravenous immunoglobulins (IVIG) 0.4 g/kg/day was administered for 5 days for the presumed diagnosis of non-paraneoplastic LE. After IVIG treatment, neurological condition did not improve. Then, we used plasmapheresis (PE) for 5 daily, followed by 3 exchanges consecutive days. After PE, IVIG 0.4 g/kg for another 5 days were administered again. After that combined treatment, we determined a dramatic improvement of his neurological symptoms.
Discussion
LE is a neurological syndrome that may present in association with cancer, infection, or as an isolate clinical conditionoften accompanying autoimmune disorders. Non-paraneoplastic LE have been described in association with autoimmune disorders. The list of autoantibodies identified in patients with nonparaneoplastic LE has been expanding. These are the antibodies targeted against cell-membrane antigens such as VGKC, novel cell-membrane antigens, the NMDAR, and GAD. [1] [2] [3] GAD autoantibodies are associated with various neurologic conditions, such as stiff person syndrome, cerebellar ataxia, LE, myasthenia gravis, and epilepsy described mainly in adults. [7, 8] Anti-GAD-associated neurological diseases are rare in children. [4] [5] [6] The pathogenic properties of GAD antibodies have not been completely elucidated. GAD is an intracytoplasmic, ratelimiting enzyme that converts the excitatory neurotransmitter glutamate into the inhibitory gamma-aminobutyric acid (GABA). [7] Two GAD isoforms (65 and 67 kDa) are found in GABAergic neurons and pancreatic b-cells. [9] GAD 65 is highlyexpressed in CA1 and the hippocampal dentate gyrus. GAD 65 is an intracellular protein, but it has been suggested that it could be exposed on the cell surface during exocytosis from GABAergic neurons, allowing a pathogenic antibody-antigen interaction to occur. It has been postulated in other anti-GAD neurologic disorders like stiff-man syndrome and cerebellar ataxia that GAD 65 antibodies impair GABAergic synaptic transmission by reducing GABA synthesis and/or interfering with exocytosis of GABA. [10, 11] There have been a report on few cases of LE with anti-GAD antibody in recent literature. [4] [5] [6] [12] [13] [14] Mishra et al. [12] reported a 15-year-old boy with non-paraneoplastic, anti-GAD-associated LE presenting with subacute headache, memory disturbance, psychiatric symptoms, and seizures. The other one, Korff et al. [13] described the case of a 6-year-old patient who had developed refractory epilepsy, developmental regression, and type 1 diabetes mellitus, in association with elevated plasma and cerebrospinal fluid GAD antibody. In another case, Akman et al. [14] reported a 16-year-old female with immune deficiency who was diagnosed with acute-onset non-neoplastic LE. Brainstem involvement had not reported in these previous studies. However, our patient presented with brainstem symptoms. To our knowledge, this is the first report of brainstem involvement of LE associated with anti-GAD in the children.
The treatment of anti-GAD-related neurological conditions relies either on enhancement of GABA activity or on immunosuppression. The treatment for associated with anti-GAD has included corticosteroids, immunosuppressants, PE, IVIG, and GABAergic drugs. [9] A large study of anti-GADrelated LE demonstrated poor response to steroid pulses. [15] Another study suggests that with the LE subtype, PE is more effective than steroids and IVIG. [5, 13] In our patient, we used combination of PE and IVIG. After treatment, we determined a dramatic improvement of the neurological findings. Korff et al. [13] found that plasmapheresis was the most effective treatment in decreasing anti-GAD levels in their patient with LE, whereas intravenous immunoglobulin and intravenous and oral corticosteroids had no effect on GABA levels or seizure frequency. As same, Mazzi et al. [5] reported that plasma exchange has effected in LE. In our patient, the use of plasma exchange had resulted in an improvement on symptoms.
In conclusion, this report underlines the importance of early diagnosis ofimmune-mediated encephalopathy and screening for specific autoantibodies. The recognition of encephalitis associated with anti-GAD is important because of the potential response to the treatment.
